GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ourofino SA (BSP:OFSA3) » Definitions » Research & Development

Ourofino (BSP:OFSA3) Research & Development : R$52 Mil (TTM As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Ourofino Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Ourofino's Research & Development for the three months ended in Mar. 2025 was R$13 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was R$52 Mil.

Ourofino Research & Development Historical Data

The historical data trend for Ourofino's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ourofino Research & Development Chart

Ourofino Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.67 58.93 69.34 59.70 49.45

Ourofino Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.90 11.16 11.83 15.55 13.03

Ourofino Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ourofino  (BSP:OFSA3) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ourofino Research & Development Related Terms

Thank you for viewing the detailed overview of Ourofino's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Ourofino Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ourofino SA (BSP:OFSA3) » Definitions » Research & Development
Comparable Companies
BSP:BLAU3 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507 UTHR NSE:TORNTPHARM BOM:500124 NBIX BOM:543904
Traded in Other Exchanges
N/A
Address
Anhanguera Highway SP 330, Block C, 2nd floor, Km 298, Industrial District, Cravinhos, SP, BRA, 14140-000
Website
https://www.ourofino.com
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.

Ourofino Headlines

No Headlines